Protalix BioTherapeutics (PLX) EBIT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.45% |
| Dec 31, 2025 | -16.20% |
| Sep 30, 2025 | 23.09% |
| Jun 30, 2025 | 20.33% |
| Mar 31, 2025 | -23.59% |
| Dec 31, 2024 | 26.79% |
| Sep 30, 2024 | 35.60% |
| Jun 30, 2024 | 16.10% |
| Mar 31, 2024 | 2.58% |
| Dec 31, 2023 | -8.87% |
| Sep 30, 2023 | 12.79% |
| Jun 30, 2023 | 38.13% |
| Mar 31, 2023 | 13.75% |
| Dec 31, 2022 | 22.71% |
| Sep 30, 2022 | 16.64% |
| Jun 30, 2022 | 12.56% |
| Mar 31, 2022 | 21.73% |
| Dec 31, 2021 | 8.13% |
| Sep 30, 2021 | 22.28% |
| Jun 30, 2021 | 1.59% |
| Mar 31, 2021 | 13.97% |
| Dec 31, 2020 | 18.82% |
| Sep 30, 2020 | 12.39% |
| Jun 30, 2020 | 16.70% |
| Mar 31, 2020 | 23.49% |
| Mar 31, 2019 | 3.07% |
| Dec 31, 2018 | 26.48% |
| Sep 30, 2018 | 7.90% |
| Jun 30, 2018 | 0.44% |
| Mar 31, 2018 | -3.07% |
| Dec 31, 2017 | 1.18% |
| Sep 30, 2017 | -6.91% |
| Jun 30, 2017 | -25.58% |
| Mar 31, 2017 | -0.97% |
| Dec 31, 2016 | 0.31% |
| Sep 30, 2016 | 5.38% |
| Jun 30, 2016 | 6.46% |
| Mar 31, 2016 | -9.31% |
| Dec 31, 2015 | 2.74% |
| Sep 30, 2015 | -11.92% |
| Jun 30, 2015 | 11.26% |